10 unknown, 7 completed, 7 recruiting, 5 active not recruiting. 20 Phase 2, 7 Phase 3, 4 Phase 1, 3 Not applicable.
Follow Thoracic Radiotherapy: new trials by email Literature Review of Thoracic Radiotherapy trials Research Report on Thoracic Radiotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer Etoposide, Cisplatin, Carboplatin - Lung, Radiotherapy | Phase 2 | Recruiting | Jiangmen Central Hospital | 43 | 2026-07-20 | 2026-09-22 |
| A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer benmelstobart, Anlotinib, Carboplatin or cisplatin - SCLC, Extensive Stage | Phase 2 | Not yet recruiting | Yayi He | 33 | 2026-04-20 | 2026-04-20 |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Recruiting | SWOG Cancer Research Network | 900 | 2025-11-06 | 2026-03-30 |
| Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy Etoposide + cisplatin/carboplatin, Thoracic radiotherapy, Prophylactic cranial irradiation (PCI) - Limited-stage Small Cell Lung Cancer (LS-SCLC) | Recruiting | Peking University Cancer Hospital & Institute | 65 | 2025-02-25 | 2025-03-11 | |
| Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC Tislelizumab, Etoposide, Carboplatin or Cisplatin - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Second Hospital of Shanxi Medical University | 40 | 2024-08-01 | 2026-04-24 |
| A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma anlotinib, Thoracic radiotherapy - Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma | Phase 2 / Phase 3 | Recruiting | Army Medical Center of PLA | 266 | 2024-03-08 | 2024-04-09 |
| First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy Thoracic Radiotherapy - Extensive-stage Small-cell Lung Cancer | Phase 2 | Unknown | Henan Cancer Hospital | 47 | 2023-12-01 | 2024-09-19 |
| Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy thoracic radiotherapy - Small Cell Lung Cancer Extensive Stage | Phase 1 | Unknown | Fudan University | 28 | 2023-12-01 | 2024-01-09 |
| PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients Prophylactic cranial irradiation, Thoracic radiotherapy, Chemotherapy - Small Cell Lung Cancer Limited Stage | Not applicable | Unknown | Zhejiang Cancer Hospital | 220 | 2023-01-01 | 2023-12-19 |
| TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors Thoracic radiotherapy - SCLC,Extensive Stage | Phase 2 | Unknown | Zhejiang Cancer Hospital | 42 | 2022-09-01 | 2022-09-16 |
| A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy - Limited-Stage Small Cell Lung Cancer | Phase 3 | Active not recruiting | Shanghai Henlius Biotech | 511 | 2022-05-17 | 2026-01-13 |
| Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) pembrolizumab/vibostolimab, durvalumab, cisplatin - Carcinoma, Non-Small-Cell Lung | Phase 3 | Completed | Merck Sharp & Dohme LLC | 610 | 2022-05-03 | 2026-08-28 |
| Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer Thoracic radiotherapy, Chemo-immunotherapy - Small-cell Lung Cancer | Phase 3 | Terminated | Norwegian University of Science and Technology | 239 | 2022-01-11 | 2026-01-28 |
| Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy Thoracic Radiotherapy, Etoposide with Carboplatin or Cisplatin, Durvalumab - Extensive-Stage Small-Cell Lung Cancer | Phase 2 | Active not recruiting | Trans Tasman Radiation Oncology Group | 35 | 2022-01-01 | 2025-08-26 |
| Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab Thoracic radiotherapy, Atezolizumab 1200 mg e.v. q21 - Small Cell Lung Cancer | Phase 2 | Recruiting | Regina Elena Cancer Institute | 37 | 2021-12-15 | 2026-06-05 |
| Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). Durvalumab, carboplatin, etoposide - Small Cell Lung Cancer, Lung Cancer | Phase 2 | Active not recruiting | Swiss Cancer Institute | 46 | 2021-06-25 | 2026-10-21 |
| Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy thoracic radiotherapy - Small-cell Lung Cancer | Not applicable | Recruiting | Ruijin Hospital | 104 | 2021-01-30 | 2026-08-12 |
| A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC Almonertinib - Non Small Cell Lung Cancer, Stage III NSCLC | Phase 2 | Unknown | First People's Hospital of Hangzhou | 43 | 2020-08-01 | 2021-01-12 |
| Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) Pembrolizumab, Olaparib, Placebo for olaparib - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 870 | 2020-07-06 | 2026-05-15 |
| Thoracic Radiotherapy Plus EGFR-TKI for Stage III EGFR-mutant Lung Adenocarcinoma Thoracic radiotherapy, EGFR-TKI - Lung Cancer Stage III, EGFR Activating Mutation | Completed | Laibin People's Hospital | 202 | 2020-01-01 | 2026-10-05 |
Showing 20 of 34. Sign in to see all of them.
Small Cell Lung Carcinoma (15) · Carcinoma, Non-Small-Cell Lung (11) · Lung Neoplasms (7) · Esophageal Neoplasms (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Radiation Pneumonitis (2) · Adenocarcinoma of Lung (1) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Esophageal Squamous Cell Carcinoma (1) · Neoplasms (1) · Respiratory Insufficiency (1)
Zhejiang Cancer Hospital (4) · First People's Hospital of Hangzhou (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Merck Sharp & Dohme LLC (2) · AHS Cancer Control Alberta (1) · Army Medical Center of PLA (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Chinese PLA General Hospital (1) · Eli Lilly and Company (1) · Fudan University (1) · Henan Cancer Hospital (1) · Jiangmen Central Hospital (1) · Laibin People's Hospital (1) · National Cancer Institute (NCI) (1) · Norwegian University of Science and Technology (1)
China (20) · United States (8) · Germany (4) · Italy (4) · Spain (4) · Canada (3) · Czechia (3) · Argentina (2) · Australia (2) · Chile (2) · Estonia (2) · France (2) · Greece (2) · Hungary (2) · Japan (2)
Alberto A Chiappori, MD (1) · Alfredo Addeo, Prof (1) · Anne C Chiang (1) · Bradford Perez, MD (1) · Don Yee, MD, FRCPC (1) · Eric Hau (1) · Gang Jin, Dr. (1) · Hui Liu, Professor (1) · Jan Nyman, Ass.prof (1) · Jingjing Wang (1) · Jinming Yu, MD (1) · Joan H. Schiller, MD (1) · Lvhua Wang, MD (1)
PMID 17406356, PMID 31040256, PMID 33026449, PMID 33962566, PMID 35618629, PMID 40623886, PMID 40769176
2019 (1), 2023 (1), U10CA021115 (1), U10CA180888 (1)